Smallcaps Investment Research

While we’re still waiting for the FDA to make a decision regarding Hemisperx Biopharma’s (HEB – $2.00) NDA for Ampligen to treat Chronic Fatigue Syndrome (CFS), mutual funds have been big buyers of HEB’s shares. In the second quarter, ending June 30, 2009, mutual funds have added 8.36 million shares of Hemispherx, or 6.6% of total shares outstanding, to their […]

At a time of year when the number of press releases is relatively low, one Company, that we have been following for some time, stood out this week with two announcements: Clearfield Inc. (CLFD – $1.77) . Clearfield, which manufactures and sells fiber distribution systems, optical components, outside plant cabinets, and fiber and copper cable assemblies for the telecommunications industry, […]

Next to Hemispherx Biopharma Inc. (+ 572% since our recommendation) and Orsus Xelent Inc (+ 65% since our recommendation), we have a few more aces up our sleeve. Take, for instance, Global Green Solutions Inc. (GGRN – $0.12) , which we first recommended at $0.06 a few months ago, is making progress in both its business units: Greensteam, a commercial […]

Our guest today is Mr. Karl Puehringer, President and CEO of Baldwin Technology Co. Inc. (BLD – $0.91). Baldwin Technology Company, Inc., together with its subsidiaries, engages primarily in the development, manufacture, and sale of process automation equipment for the printing and publishing industry. Mr. Puehringer discusses the Company and the markets it operates in. Click the start button underneath […]

A few weeks ago, we wrote Hemispherx Biopharma’s (HEB – $2.73) shares were on a rollercoaster and it seems the ride is getting wilder and wilder. Obviously, there’s a tremendous amount of speculation about the FDA’s decision to approve Ampligen for Chronic Fatigue Syndrome (CFS). Based on all the public information out there, you have to form an opinion, and […]

We recommended Orsus Xelent Technologies Inc. (ORS – $0.91) on January 10, 2009, at $0.47 as one of our three stocks for 2009. Although there was no real catalyst, the stock went up almost 50% this week. The Company did report strong first quarter results on May 20th and this week’s jump may be a late reaction to it. We […]

For many this is starting to look like a soap opera, but contrary to the TV version, this is extremely exciting. Obviously, we’re talking about Hemispherx Biopharma (HEB) and the big question will the FDA give its thumbs up to bring Ampligen to the market. The introduction to the next episode was given on Tuesday morning when HEB issued a […]

Orsus Xelent Technologies, Inc. (ORS) our designer and manufacturer of mobile phones for the Asian market, announced that its first quarter revenues declined about 4.8% compared with the same period last year to $19.7 million. However, the Company’s net income rose 11.4% to $2.2 million or 7 cents per share. In these market circumstances, that’s a great performance! These numbers […]

Most Hemispherx Biopharma (HEB) shareholders must be feeling sick after being on a rollercoaster ride an entire week. The stock went up and down and traded more than 90 million shares only to finish 1 cent below where it closed last Friday. Two months ago, barely 200,000 shares changed hands in a week’s time. On Tuesday, the Company announced a […]